Wang, K., Kong, C., Zhang, J., Sun, L., Xuan, Q., Huang, H. (2026). A first-in-human (FIH), phase I/II open-label, dose-escalation and -expansion study of ILKN421H, an LNP mRNA encoding an IL2Rβγ selective IL-2v, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.8556